A pharmaceutical company that makes and sells prescription drugs centred on psychiatric and neurological medicines, together with cardiovascular, peptic ulcer, osteoporosis and anti-inflammatory analgesic products.
01
Products & pipeline
Whanin Atomoxetine Tablet
Marketed
Atomoxetine tablet for ADHD; all six strengths (10, 18, 25, 40, 60 and 80 mg) were launched in Korea in July 2026. It is the first atomoxetine tablet formulation approved in Korea and is used in children aged 6 and over and in adults.
Hyangnam Plant (Hwaseong)
Service
Hyangnam plant acquired from Janssen in November 2020; it received a GMP compliance certificate in February 2023 and expanded its finished-goods warehouse in February 2024. The company is adding blister packaging equipment there for exports.
Anseong Plant
Service
Anseong plant is a production site for drug manufacturing, packaging and quality control; its automated warehouse expansion was completed in September 2024.
Central Research Institute (Yongin)
Service
Central Research Institute on Gwanggyojungang-ro, Suji-gu, Yongin, Gyeonggi-do, handling formulation research, medicinal chemistry and bioequivalence evaluation; the research center opened in January 2023.
Bifido
Stage unconfirmed
Acquired Bifido, a company specialising in Bifidobacterium, in August 2024.
02
Recent developments
Announced
Announced it is scaling up exports of central nervous system products through its collaboration with global generics company TEVA, and, on the basis of renewed EAEU GMP certification, is pursuing the EAEU market and CDMO work for local drugmakers there.
Announced
Launched Whanin Atomoxetine Tablet, the first atomoxetine tablet approved in Korea, in six strengths.
03
Experience in official career sources
Individual vacancy
Pharmacists for plants and research (open until filled)
Applications observed open
Observed 2026-10-26 · Application window Date unconfirmed — 2026-12-31
Work
Hires pharmacists for five roles (quality management, manufacturing management, formulation research, analytical research and regulatory affairs); work locations are the Anseong and Hwaseong plants, the Yongin research institute and the Seoul head office.
Experience & requirements
Requires a four-year degree or higher and a pharmacist licence; new and experienced applicants are welcome. Pharmaceutics or polymer majors are preferred for formulation research, chemistry or biology for analytical research, and English communication and overseas business skills for regulatory affairs.
Talent pool
Year-round talent pool registration
Applications observed open
Observed 2026-10-26
Work
Accepts applications year-round for production (process and packaging), production planning, quality assurance and control, sales, marketing and business development, research (formulation, synthesis, bioequivalence), and global business and regulatory roles.
Experience & requirements
Requirements range by role from a high-school diploma (production) to a four-year or master's degree (research); 3 to 10 years of experience and English are preferred for quality roles, and English plus Japan or Europe market experience for global business.
Information from a role guide does not establish a current vacancy.
Sources & coverage 12
A brief based on selected official material, not an exhaustive product or vacancy list.
환인제약 ↗환인제약 · Published Date unconfirmed · Sources checked 2026-10-26
Whanin Pharmaceutical ↗Whanin Pharmaceutical · Published Date unconfirmed · Sources checked 2026-10-26
사업 소개 ↗환인제약 · Published Date unconfirmed · Sources checked 2026-10-26
![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}